UPSC MainsMEDICAL-SCIENCE-PAPER-II201910 Marks150 Words
Q20.

Describe pointwise management of a case of Stevens-Johnson Syndrome (SJS).

How to Approach

This question requires a systematic, pointwise approach to the management of Stevens-Johnson Syndrome (SJS). The answer should cover initial assessment, supportive care, specific therapies, and monitoring. Prioritize a structured format using headings and bullet points for clarity. Focus on practical steps a clinician would take, including identifying and removing the causative agent, managing skin and mucosal involvement, and preventing complications. Mention scoring systems like SCORTEN.

Model Answer

0 min read

Introduction

Stevens-Johnson Syndrome (SJS) and its more severe form, Toxic Epidermal Necrolysis (TEN), are rare, life-threatening mucocutaneous reactions typically triggered by medications or infections. Characterized by widespread epidermal detachment, SJS/TEN requires prompt diagnosis and aggressive management to reduce morbidity and mortality. Early identification of the offending agent and supportive care are crucial. The distinction between SJS and TEN is based on the percentage of body surface area (BSA) affected – SJS involves <10% BSA detachment, TEN >30%, and overlap SJS/TEN involves 10-30%.

Pointwise Management of Stevens-Johnson Syndrome (SJS)

The management of SJS is multifaceted and requires a multidisciplinary approach. The following points outline the key aspects of care:

1. Initial Assessment & Stabilization

  • Diagnosis: Clinical diagnosis based on characteristic skin lesions and mucosal involvement. Biopsy can confirm diagnosis but should not delay treatment.
  • Causative Agent Identification: Thorough medication history and investigation for potential infectious triggers. Immediate discontinuation of suspected drugs.
  • Severity Assessment: Utilize scoring systems like SCORTEN (Score for Toxic Epidermal Necrolysis) to assess prognosis and guide management.
  • Airway Management: Assess for airway compromise due to mucosal involvement. Early intubation may be necessary.
  • Fluid Resuscitation: Aggressive intravenous fluid resuscitation to address fluid loss from skin damage. Monitor urine output closely.

2. Supportive Care

  • Wound Care: Similar to burn management. Sterile dressings, debridement of necrotic skin (avoid aggressive debridement). Silver sulfadiazine or biosynthetic dressings can be used.
  • Pain Management: Adequate analgesia is crucial. Opioids may be required.
  • Nutritional Support: Early enteral nutrition is preferred. Parenteral nutrition may be necessary if enteral route is not feasible.
  • Infection Control: Strict infection control measures. Prophylactic antibiotics are generally *not* recommended, but treat any documented infections aggressively.
  • Ophthalmological Care: Frequent ophthalmological examinations to prevent corneal damage. Lubricating eye drops and topical steroids may be used.
  • Oral Hygiene: Meticulous oral hygiene to prevent secondary infections.

3. Specific Therapies (Controversial & Evolving)

  • Intravenous Immunoglobulin (IVIG): May be beneficial in early stages, particularly in children. Evidence is mixed.
  • Corticosteroids: Use is controversial. Some studies suggest benefit if administered early, while others show increased risk of infection.
  • Cyclosporine: Emerging evidence suggests potential benefit in reducing mortality.
  • Plasma Exchange: May remove causative agents or inflammatory mediators, but evidence is limited.

4. Monitoring

  • Vital Signs: Continuous monitoring of vital signs, including heart rate, blood pressure, and respiratory rate.
  • Fluid Balance: Strict monitoring of fluid intake and output.
  • Electrolytes: Frequent monitoring of electrolytes.
  • Skin & Mucosal Involvement: Daily assessment of BSA detachment and mucosal involvement.
  • Signs of Infection: Vigilant monitoring for signs of secondary infection.
  • Organ Function: Monitor renal and hepatic function.

5. Long-Term Follow-up

  • Skin Pigmentation Changes: Patients may experience post-inflammatory hyperpigmentation.
  • Scarring: Potential for scarring, requiring dermatological management.
  • Ocular Sequelae: Long-term ophthalmological follow-up to monitor for chronic ocular complications.

Conclusion

Effective management of SJS requires a rapid, multidisciplinary approach focused on identifying and eliminating the causative agent, providing aggressive supportive care, and considering adjunctive therapies based on individual patient factors and evolving evidence. Early recognition, prompt intervention, and meticulous monitoring are crucial for improving patient outcomes and minimizing long-term sequelae. Ongoing research is needed to refine treatment strategies and improve our understanding of this life-threatening condition.

Answer Length

This is a comprehensive model answer for learning purposes and may exceed the word limit. In the exam, always adhere to the prescribed word count.

Additional Resources

Key Definitions

SCORTEN
SCORTEN (Score for Toxic Epidermal Necrolysis) is a scoring system used to assess the severity of SJS/TEN and predict mortality risk. It incorporates factors like age, heart rate, renal function, BSA detachment, and bicarbonate levels.
Toxic Epidermal Necrolysis (TEN)
TEN is a severe form of SJS characterized by >30% total body surface area (TBSA) detachment of the epidermis, resembling a full-thickness burn.

Key Statistics

The incidence of SJS is estimated to be 1-6 cases per million person-years, while TEN occurs in 0.4-1.2 cases per million person-years. (Based on knowledge cutoff 2023)

Source: American Academy of Dermatology

Mortality rates for SJS range from 1-5%, while TEN has a mortality rate of 25-35%. (Based on knowledge cutoff 2023)

Source: UpToDate

Examples

Allopurinol-Induced SJS

Allopurinol is a common cause of SJS, particularly in patients with renal impairment. A patient started on allopurinol for gout develops a widespread rash, fever, and mucosal ulcers. Immediate discontinuation of allopurinol and supportive care are essential.

Frequently Asked Questions

Is SJS contagious?

No, SJS is not contagious. It is a reaction to a trigger, not an infectious disease.

Topics Covered

DermatologyMedicineSJSManagementSupportive Care